These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34043467)

  • 1. CD123-targeted therapy in acute myeloid leukemia.
    Espinoza-Gutarra MR; Green SD; Zeidner JF; Konig H
    Expert Rev Hematol; 2021 Jun; 14(6):561-576. PubMed ID: 34043467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD123 bi-specific antibodies in development in AML: What do we know so far?
    Slade MJ; Uy GL
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101219. PubMed ID: 33279175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16
    Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
    Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
    Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
    J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
    Aldoss I; Clark M; Song JY; Pullarkat V
    Hum Vaccin Immunother; 2020 Oct; 16(10):2341-2348. PubMed ID: 32692611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia.
    Xu S; Zhang M; Fang X; Hu X; Xing H; Yang Y; Meng J; Wen T; Liu J; Wang J; Wang C; Xu H
    ACS Appl Mater Interfaces; 2022 Aug; 14(34):38584-38593. PubMed ID: 35977045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
    Pelosi E; Castelli G; Testa U
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S; Daver N; Ravandi F
    Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
    Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
    Wang M; Wu H; Duan M; Yang Y; Wang G; Che F; Liu B; He W; Li Q; Zhang L
    Life Sci; 2019 Sep; 232():116663. PubMed ID: 31323275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
    Abaza Y; Fathi AT
    Cancer J; 2022 Jan-Feb 01; 28(1):37-42. PubMed ID: 35072372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.